Semaglutide

Cosa succede davvero quando si sospendono i farmaci per dimagrire? – Mondosanità

by

When patients stop taking modern anti-obesity medications, the physiological changes often reverse rapidly, raising critical questions about long-term management for chronic conditions. Recent clinical insights from medical journals and healthcare reporting highlight that discontinuing treatments such as GLP-1 receptor agonists frequently leads to significant weight regain and shifts in body composition. According to data and … Read more

위고비, 살만 빠지는 게 아니었다?! – 동아사이언스

by

Semaglutide, the active ingredient in the weight-loss medication Wegovy, is demonstrating significant potential in treating metabolic dysfunction-associated steatohepatitis (MASH), a progressive form of liver disease. While originally developed for chronic weight management and type 2 diabetes, clinical data indicates that the drug’s mechanism—mimicking the glucagon-like peptide-1 (GLP-1) hormone—may address the underlying liver inflammation and fibrosis … Read more

GLP-1 and Obesity Treatment: Metabolic Health, Long-Term Therapy, and Future Innovations

by

For decades, the global approach to treating obesity was framed primarily as a battle of willpower. Patients were told to “eat less and move more,” a mantra that often ignored the complex biological drivers of weight gain and the stubborn nature of metabolic adaptation. However, a pharmacological shift is currently underway, transforming obesity from a … Read more